To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol

Phase 1 Completed 28 enrolled Astellas Pharma Inc

Non-randomizedCrossoverOpen-label

Summary

The study aims to compare blood and urine concentrations of mirabegron (YM178) in healthy poor or extensive metabolizers for CYP2D6 and to evaluate if blood levels of metoprolol change whilst being dosed at the same time with daily miragebron.

Timeline

Start: 2002-09
Primary completion: 2002-11
Completion: 2002-11

Publications

Background Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M. The effect of mirabegron, a potent and selective beta3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1. Epub 2013 Jun 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metoprolol	Other / unclassified	—	Oral
Subject	Mirabegron	Other / unclassified	—	Oral

Indications

No indication recorded.